Biocon launches Bosaya, Aukelso in US

07 Apr 2026 Evaluate

Biocon has launched Bosaya (denosumab-kyqq) and Aukelso (denosumab-kyqq) in the United States (US). Bosaya (biosimilar to Prolia) and Aukelso (biosimilar to Xgeva) are now available by prescription nationwide through specialty pharmacies and healthcare providers. Both products have been previously approved and granted interchangeable designation by the U.S. Food and Drug Administration in September 2025, allowing substitution at the pharmacy level in accordance with state laws.

Denosumab products play a critical role in bone health, treating osteoporosis and bone complications associated with cancer. In 2024, denosumab products generated approximately $5 billion in U.S. sales, reflecting the growing need for accessible treatment options.

Biocon is India’s largest and Asia’s leading Biotechnology Company with a strategic focus on biopharmaceuticals and research services. It is a fully integrated, innovation driven biopharma enterprise offering affordable solutions for chronic diseases to patient's worldwide. 


Biocon Share Price

350.00 9.85 (2.90%)
08-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1713.60
Dr. Reddys Lab 1191.45
Cipla 1215.80
Zydus Lifesciences 891.55
Lupin 2293.55
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×